A new hi-tech prostate cancer drug has already demonstrated a 'positive impact on the quality of life', the Institute of Cancer Research said today, as the treatment trials in the capital.
Professor Johann de Bono from the institute, who led the Affirm trial, said:
"Enzalutamide is a much needed development in prostate cancer treatment and will provide a new option for the increasing number of men with advanced prostate cancer in the UK whose disease has become resistant to first-line hormonal treatments and who have had docetaxel chemotherapy.
"Enzalutamide has already demonstrated a positive impact on quality of life whilst increasing the life-span of patients with this common disease.
"It's use will bring significant benefits, establishing it as a key component of advanced prostate cancer treatment in the UK."
More top news
A coffee shop in Fitzrovia is allowing customers to buy discounted hot drinks and pass them on to a homeless person
A man has been jailed for seven years for raping a woman after she fell asleep on a night bus in Hampstead
Police are trying to find a man who beat a woman so badly on a DLR train that her front teeth were broken and glasses smashed